{"id":"https://openalex.org/W3135007917","doi":"https://doi.org/10.1200/jco.2021.39.6_suppl.tps189","title":"PLANETTE: A modular phase IIa multicenter open-label study evaluating the ATR inhibitor ceralasertib (AZD6738) in ATM mutant advanced solid tumors.","display_name":"PLANETTE: A modular phase IIa multicenter open-label study evaluating the ATR inhibitor ceralasertib (AZD6738) in ATM mutant advanced solid tumors.","publication_year":2021,"publication_date":"2021-02-20","ids":{"openalex":"https://openalex.org/W3135007917","doi":"https://doi.org/10.1200/jco.2021.39.6_suppl.tps189","mag":"3135007917"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2021.39.6_suppl.tps189","doi":"https://doi.org/10.1200/jco.2021.39.6_suppl.tps189","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2021.39.6_suppl.tps189","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062426672","display_name":"Wassim M. Abida","orcid":"https://orcid.org/0000-0002-9006-7043","observed_orcids":["https://orcid.org/0000-0002-9006-7043"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wassim Abida","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026610874","display_name":"Elkhan Sanay","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Elkhan Sanay","raw_affiliation_strings":["AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020754942","display_name":"Natalia Lukashchuk","orcid":"https://orcid.org/0009-0006-6678-0072","observed_orcids":["https://orcid.org/0009-0006-6678-0072"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Natalia Lukashchuk","raw_affiliation_strings":["AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082781519","display_name":"Andrew J. Pierce","orcid":"https://orcid.org/0000-0001-9062-0307","observed_orcids":["https://orcid.org/0000-0001-9062-0307","https://orcid.org/0000-0003-0942-0370","https://orcid.org/0000-0002-0738-2756"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Andrew Pierce","raw_affiliation_strings":["AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057200390","display_name":"Wessel de Graaf","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Wessel de Graaf","raw_affiliation_strings":["AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055277039","display_name":"Alan Lau","orcid":"https://orcid.org/0000-0003-1055-9812","observed_orcids":["https://orcid.org/0000-0003-1055-9812"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alan Lau","raw_affiliation_strings":["AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077998778","display_name":"Vidalba Rocher-Ros","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Vidalba Rocher Ros","raw_affiliation_strings":["AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057057927","display_name":"Nisha Kurian","orcid":"https://orcid.org/0000-0002-8384-9928","observed_orcids":["https://orcid.org/0000-0002-8384-9928"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nisha Kurian","raw_affiliation_strings":["AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112615847","display_name":"Graeme Parr","orcid":"https://orcid.org/0009-0000-1843-4809","observed_orcids":["https://orcid.org/0009-0000-1843-4809"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Graeme Parr","raw_affiliation_strings":["AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018568000","display_name":"Bienvenu Loemb\u00e9","orcid":"https://orcid.org/0009-0001-2557-8170","observed_orcids":["https://orcid.org/0009-0001-2557-8170"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Bienvenu LoembE","raw_affiliation_strings":["AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000462280","display_name":"Emma Jane Dean","orcid":"https://orcid.org/0000-0001-9956-257X","observed_orcids":["https://orcid.org/0000-0001-9956-257X"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Emma Dean","raw_affiliation_strings":["AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5081123075","display_name":"Rahul Raj Aggarwal","orcid":"https://orcid.org/0000-0001-7003-7982","observed_orcids":["https://orcid.org/0000-0001-7003-7982"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rahul Raj Aggarwal","raw_affiliation_strings":["University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"39","issue":"6_suppl","first_page":"TPS189","last_page":"TPS189"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.7139000296592712,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.7139000296592712,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.259799987077713,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.009600000455975533,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ceralasertib","display_name":"ceralasertib","score":0.9610000252723694},{"id":"https://openalex.org/keywords/azd6738","display_name":"AZD6738","score":0.9700000286102295},{"id":"https://openalex.org/keywords/atr-inhibitors","display_name":"ATR inhibitors","score":0.8550000190734863},{"id":"https://openalex.org/keywords/atm-mutations","display_name":"ATM mutations","score":0.7720000147819519},{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.9559999704360962},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8379999995231628},{"id":"https://openalex.org/keywords/dna-damage-response","display_name":"DNA damage response","score":0.7789999842643738},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.5989999771118164},{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":0.871999979019165},{"id":"https://openalex.org/keywords/metastatic-prostate-cancer","display_name":"metastatic prostate cancer","score":0.48500001430511475},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.5649999976158142},{"id":"https://openalex.org/keywords/metastatic-bladder-cancer","display_name":"metastatic bladder cancer","score":0.46399998664855957},{"id":"https://openalex.org/keywords/metastatic-lung-cancer","display_name":"metastatic lung cancer","score":0.47999998927116394},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.49399998784065247},{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":0.503000020980835},{"id":"https://openalex.org/keywords/metastatic-lymphoma","display_name":"metastatic lymphoma","score":0.4300000071525574},{"id":"https://openalex.org/keywords/metastatic-endometrial-cancer","display_name":"metastatic endometrial cancer","score":0.5550000071525574},{"id":"https://openalex.org/keywords/metastatic-ovarian-cancer","display_name":"metastatic ovarian cancer","score":0.43299999833106995},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.4830000102519989},{"id":"https://openalex.org/keywords/metastatic-hepatocellular-carcinoma","display_name":"metastatic hepatocellular carcinoma","score":0.5580000281333923},{"id":"https://openalex.org/keywords/metastatic-sarcoma","display_name":"metastatic sarcoma","score":0.4959999918937683},{"id":"https://openalex.org/keywords/metastatic-small-cell-lung-cancer","display_name":"metastatic small cell lung cancer","score":0.5270000100135803},{"id":"https://openalex.org/keywords/metastatic-neuroendocrine-tumors","display_name":"metastatic neuroendocrine tumors","score":0.527999997138977},{"id":"https://openalex.org/keywords/metastatic-thyroid-carcinoma","display_name":"metastatic thyroid cancer","score":0.4230000078678131},{"id":"https://openalex.org/keywords/metastatic-head-and-neck-cancer","display_name":"metastatic head and neck cancer","score":0.5509999990463257},{"id":"https://openalex.org/keywords/metastatic-pancreatic-cancer","display_name":"metastatic pancreatic cancer","score":0.4399999976158142}],"concepts":[{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.697265625},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.6469297409057617},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5551860928535461},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5056130886077881},{"id":"https://openalex.org/C2779486608","wikidata":"https://www.wikidata.org/wiki/Q387082","display_name":"Ataxia-telangiectasia","level":4,"score":0.48202240467071533},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47295400500297546},{"id":"https://openalex.org/C178169997","wikidata":"https://www.wikidata.org/wiki/Q2892636","display_name":"Genome instability","level":4,"score":0.45834609866142273},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.4543745219707489},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.332356333732605},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.2934398651123047},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.17891788482666016},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1410858929157257},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2021.39.6_suppl.tps189","doi":"https://doi.org/10.1200/jco.2021.39.6_suppl.tps189","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2021.39.6_suppl.tps189","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4388446614","https://openalex.org/W3029290509","https://openalex.org/W4210508140","https://openalex.org/W4245056182","https://openalex.org/W3203762158","https://openalex.org/W7128790995","https://openalex.org/W6995793351","https://openalex.org/W4417070739","https://openalex.org/W3203403210","https://openalex.org/W3161453886"],"abstract_inverted_index":{"TPS189":[0],"Background:":[1],"Ataxia":[2],"telangiectasia":[3,8],"mutated":[4],"(ATM)":[5],"and":[6,9,30,51,61,70,166,296,316,347,354,369,374],"ataxia":[7],"Rad3-related":[10],"(ATR)":[11],"are":[12,53,340],"kinases":[13],"that":[14,40,251,350],"orchestrate":[15],"cellular":[16],"responses":[17],"to":[18,34,43,65,205,285,383],"DNA":[19,26,39,71],"damage.":[20],"ATM":[21,50,151,187,214,287,292,297],"is":[22,32,75,123,234,381],"primarily":[23],"activated":[24,54],"by":[25,55,294],"double":[27],"strand":[28],"breaks,":[29],"ATR":[31,52,91,260],"recruited":[33],"regions":[35],"of":[36,81,90,121,129,146,208,224,291,367],"single":[37],"stranded":[38],"arise":[41],"due":[42],"collapsed":[44],"or":[45,201,267],"stalled":[46],"replication":[47],"forks.":[48],"Although":[49],"distinct":[56],"pathways,":[57],"their":[58],"downstream":[59],"targets":[60],"effects":[62],"partially":[63],"overlap":[64],"activate":[66],"cell":[67],"cycle":[68],"checkpoints":[69],"damage":[72],"repair.":[73],"Ceralasertib":[74],"a":[76,125,144,235,333],"potent,":[77],"oral,":[78],"selective":[79],"inhibitor":[80,261],"ATR.":[82],"Pre-clinical":[83],"studies":[84],"have":[85,329],"consistently":[86],"demonstrated":[87],"synthetic":[88],"lethality":[89],"inhibitors,":[92],"including":[93,221],"ceralasertib,":[94],"in":[95,131,135,198,213,246,263,271,344,360,385],"ATM-deficient":[96],"models":[97],"across":[98,216],"multiple":[99,217],"tumor":[100,219],"types":[101],"(Kwok":[102],"et":[103,107,111,115,184],"al":[104,108,112,116,185],"2017,":[105,109],"Min":[106],"Lloyd":[110],"2020,":[113],"Hustedt":[114],"2019).":[117,186],"Early":[118],"clinical":[119,175],"evidence":[120],"efficacy":[122],"from":[124],"phase":[126,237],"I":[127],"study":[128,241,258],"ceralasertib":[130,262],"combination":[132],"with":[133,143,162,169,248,265,310,325],"olaparib":[134],"relapsed,":[136],"refractory":[137],"cancer":[138,278],"(NCT02576444).":[139],"Amongst":[140],"5":[141],"participants":[142,173],"range":[145],"solid":[147,218,312],"tumors":[148,264,313],"harboring":[149],"deleterious":[150,266,269],"mutations,":[152],"there":[153],"was":[154],"1":[155,167,256],"complete":[156],"response,":[157,368],"3":[158],"stable":[159],"diseases":[160],"(1":[161],"minor":[163],"response":[164,244,349,356],"20-30%)":[165],"patient":[168],"disease":[170],"progression.":[171],"Two":[172],"had":[174],"benefit":[176],"ongoing":[177],"for":[178,195],"more":[179],"than":[180],"12":[181],"months":[182],"(Eder":[183],"deficiency":[188],"may":[189],"be":[190,275,301,378],"detected":[191],"through":[192,202],"genomic":[193],"testing":[194,299],"loss-of-function":[196],"alterations":[197,212],"the":[199,259],"gene,":[200],"immunohistochemical":[203],"methods":[204],"detect":[206,286],"loss":[207],"protein":[209],"expression.":[210],"Genomic":[211],"occur":[215],"types,":[220],"approximately":[222],"4%":[223],"advanced":[225,249,311],"prostate":[226,317],"cancers.":[227],"Methods:":[228],"PLANETTE":[229],"(clinicaltrials.gov":[230],"identifier":[231],"(NCT":[232],"04564027)":[233],"modular":[236],"2a":[238],"multicenter":[239],"open-label":[240],"investigating":[242],"DNA-damage":[243],"agents":[245],"patients":[247,309,324],"cancers":[250],"harbor":[252],"molecular":[253,283],"alterations.":[254],"Module":[255],"will":[257,274,300,306,321,377],"suspected":[268],"mutations":[270],"ATM.":[272],"Patients":[273],"identified":[276],"at":[277],"centers":[279],"which":[280],"routinely":[281],"perform":[282],"profiling":[284],"mutations.":[288],"Central":[289],"confirmation":[290],"mutation":[293],"NGS":[295],"IHC":[298],"conducted":[302],"retrospectively.":[303],"Cohort":[304,345,361],"A":[305,346],"enroll":[307],"~25":[308],"(except":[314],"NSCLC":[315],"cancer),":[318],"cohort":[319],"B":[320],"include":[322,365],"~27":[323],"metastatic":[326],"CRPC":[327],"who":[328],"previously":[330],"progressed":[331],"on":[332],"novel":[334],"hormonal":[335],"agent.":[336],"The":[337],"primary":[338],"endpoints":[339,364],"investigator":[341],"assessed":[342],"ORR":[343],"composite":[348],"includes":[351],"radiographic,":[352],"PSA,":[353],"CTC":[355],"per":[357],"PCWG":[358],"criteria":[359],"B.":[362],"Secondary":[363],"duration":[366],"progression":[370],"free":[371],"survival.":[372],"Pharmacodynamic":[373],"other":[375],"biomarkers":[376],"explored.":[379],"Enrolment":[380],"planned":[382],"start":[384],"November":[386],"2020.":[387],"Clinical":[388],"trial":[389],"information:":[390],"04564027.":[391]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2021-03-15T00:00:00"}